NT5E and cancer: CD73 is overexpressed in many cancers 19 and anti-CD73 mAb therapy has been shown to block conversion of AMP into adenosine and to enhance the activity of anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors 20, 21.